Clinical Trials Logo

Common Variable Immunodeficiency clinical trials

View clinical trials related to Common Variable Immunodeficiency.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05481554 Not yet recruiting - Vascular Diseases Clinical Trials

Composition and Function of Gut Microbiota in Porto-sinusoidal Vascular Disease Associated With Variable Common Immunodeficiency

MI-MVPS
Start date: July 2022
Phase:
Study type: Observational

This aim of this study is the evaluation of the gut microbiota imbalance occurrence and its characterization in patients with common variable immunodeficiency associated to an enteropathy with or without porto-sinusoidal vascular disease.

NCT ID: NCT02680652 Not yet recruiting - Clinical trials for Common Variable Immune Deficiency (CVID)

Improving the Diagnosis of Common Variable Immune Deficiency

Start date: February 2016
Phase: N/A
Study type: Observational

This is an observational, case--control study with a single blood draw among two cohorts, patients with CVID and healthy controls. Samples will be analyzed by cytometry (CyTOF) to simultaneously examine the major signaling pathways of all circulating innate and adaptive immune cell types as well as whole exome sequencing. The goal is to improve our general understanding of the human immune response to infections and the diagnosis of CVID.

NCT ID: NCT02661477 Not yet recruiting - Clinical trials for Rhinovirus Infection

Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial

Hypogamma Int1
Start date: May 2016
Phase: Phase 2
Study type: Interventional

The study will investigate the efficacy and safety of subcutaneous interferon alpha -2a to eradicate rhinovirus in patients with primary hypogammaglobulinemia. Patients with hypogammaglobulinemia have persistent rhinovirus infections. Rhinovirus may worsen pulmonary complications. Pegylated interferon alpha with ribavirin appear to effectively clear persistent rhinovirus infections in hypogammaglobulinemia patients. Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection will be randomly assigned in a double-blind fashion to receive either - Group 1: subcutaneous pIFNα2a - Group 2: subcutaneous placebo Subjects will have scheduled study visits at 1-week and at 2-month after entry to study. In addition, possible bacterial infections will be treated with antibiotics. Each patient will be followed with weekly nasal surveillance samples for 2 months and a symptom diary. Blood draws take place at study entry, 1-week and 2-month time-points.